Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Stentys SA Announces Board Changes

Thursday, 28 Mar 2013 02:30am EDT 

Stentys SA announced that following the FDA approval of its clinical trial in the United States, a decisive development milestone, Professor Jacques S├ęguin decided to step down as a Director to focus on new early-stage projects and proposed to join the Scientific Advisory Board in order to continue advising STENTYS` clinical strategy. The Board of Directors has unanimously voted Michel Darnaud, as its new Chairman. 

Company Quote

-0.9 -12.40%
1 Aug 2014